Cover Image

Progression or suppression: two sides of the innate lymphoid cells in cancer

Innate lymphoid cells (ILCs) as key players in innate immunity have been shown to be significantly associated with inflammation, lymphoid neogenesis, tissue remodeling, mucosal immunity and lately have been considered a remarkable nominee for either tumor-promoting or tumor-inhibiting functions. Thi...

Full description

Saved in:
Bibliographic Details
Main Authors: Hosseini, S. Haleh (Author) , Sharafkandi, Nadia (Author) , Seyfizadeh, Narges (Author) , Hemmatzadeh, Maryam (Author) , Marofi, Faroogh (Author) , Shomali, Navid (Author) , Karimi, Mohammad (Author) , Mohammadi, Hamed (Author)
Format: Article (Journal)
Language:English
Published: 2020
In: Journal of cellular biochemistry
Year: 2019, Volume: 121, Issue: 4, Pages: 2739-2755
ISSN:1097-4644
DOI:10.1002/jcb.29503
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1002/jcb.29503
Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/jcb.29503
Get full text
Author Notes:S. Haleh Hosseini, Nadia Sharafkandi, Narges Seyfizadeh, Maryam Hemmatzadeh, Faroogh Marofi, Navid Shomali, Mohammad Karimi, Hamed Mohammadi
Description
Summary:Innate lymphoid cells (ILCs) as key players in innate immunity have been shown to be significantly associated with inflammation, lymphoid neogenesis, tissue remodeling, mucosal immunity and lately have been considered a remarkable nominee for either tumor-promoting or tumor-inhibiting functions. This dual role of ILCs, which is driven by intrinsic and extrinsic factors like plasticity of ILCs and the tumor microenvironment, respectively, has aroused interest in ILCs subsets in past decade. So far, numerous studies in the cancer field have revealed ILCs to be key players in the initiation, progression and inhibition of tumors, therefore providing valuable insights into therapeutic approaches to utilize the immune system against cancer. Herein, the most recent achievements regarding ILCs subsets including new classifications, their transcription factors, markers, cytokine release and mechanisms that led to either progression or inhibition of many tumors have been evaluated. Additionally, the available data regarding ILCs in most prevalent cancers and new therapeutic approaches are summarized.
Item Description:03 November 2019
Gesehen am 11.05.2020
Physical Description:Online Resource
ISSN:1097-4644
DOI:10.1002/jcb.29503

Similar Items